Date: Mar 2022
Date: Mar 2022
The Market Statsville Group (MSG) publishes the new report on the "Artificial Insemination Market by Type Outlook (Intrauterine Insemination, Intracervical Insemination, Intravaginal Insemination, and Intratubal Insemination), by Source Type (AIH-Husband and AID-Donor), by End-Use (Fertility Clinics & Others and Home), by Region – Global Share and Forecast to 2030". The global artificial insemination market size is expected to grow from USD 1,929.2 million in 2021 to USD 3,677.9 million by 2030, at a CAGR of 8.4% during the forecast period. The market for artificial insemination is projected to grow in the coming years. In countries such as the U.S., Canada, and India, couples can now use ARTs to conceive. ARTs are fertility treatment procedures that include treatment techniques such as Intracytoplasmic Sperm Injection (ICSI), cryopreservation of embryos or gametes, and use of fertility medication. In sperm banks, couples belonging to different communities can use a single vial of sperm to conceive at around USD 300 to USD 4000.
Moreover, couples can opt for donor eggs for around USD 37,000 to USD 65,000, inclusive of services such as consultancy fees and medical expenses. In addition, several medical insurance plans cover the cost of artificial insemination, which is driving the market growth. Artificial insemination has become easier and more affordable with the availability of at-home fertility kits.
The overall artificial insemination market has been segmented into the type, source type, end-use, and region.
Fertility clinics, by end-use, is estimated to hold the largest market share during the forecast period
Based on end-use, the global artificial insemination market is segmented into fertility clinics & others and home. Fertility clinics held the majority of the market share of 67.1% in the year 2021 and is likely to be the fastest end-use segment over the forecast period. All types of artificial insemination procedures can be performed at fertility clinics. Mostly Intrauterine Insemination (IUI) and Intratubal Insemination (ITI) procedures are performed in fertility clinics. Insemination procedures at clinics involve consultation, which includes the determination of the ovulation cycle before initiating the procedures. In addition, doctors can prescribe fertility medications to increase the chances of conception. Unwashed sperm samples can cause painful cramping. Hence, fertility clinics also provide sperm washing, a process to prepare sperm samples for insemination, by eliminating impurities from the semen sample.
Europe accounts for the largest market share in artificial insemination market 2021
Based on the regions, the global artificial insemination market has been segmented across North America, Asia-Pacific, Europe, South America, and the Middle East & Africa. In 2021, Europe accounted for the highest market share of 38.7% in the global artificial insemination market and was anticipated to maintain its dominance throughout the forecast period. In Europe, the fertility rate has constantly been declining over the years. The average fertility rate in Europe is 1.6 children per woman. In addition, the number of couples reporting infertility has been increasing by around 8% to 9% each year, making infertility a public health concern. A higher number of couples are opting for ARTs. Around 5% of the children born in Europe result from ARTs.
In the UK, around 13% of women and 10% of men have experienced infertility at some point. Of those experiencing infertility, 57% of women and 53% of men have opted for medical consultation. According to the National Institute for Health and Care Excellence (NICE), 25% of the infertility cases in the UK are unexplained, 45% result from ovulatory or tubal disorders, 10% from uterine disorders, and 10% from male infertility. More than 2,000 babies are born each year in the UK using artificial insemination procedures.
This research report includes a study on the development and marketing strategies, along with a study on the product portfolios and winning strategies of the leading companies operating in the artificial insemination market. It also consists of the profiles of leading companies such as Rinovum Women’s Health, LLC, Genea Limited, FUJIFILM Irvine Scientific, Pride Angel, KITAZATO CORPORATION, Vitrolife, and Rocket Medical plc.
Browse complete report: https://www.marketstatsville.com/artificial-insemination-market
About Market Statsville Group
Market Statsville Group (MSG) is a business research and consulting platform of Statsville Consulting Private Limited, based in Oklahoma, USA. MSG is the leading market research and strategy builder with the depth and breadth of solutions that perfectly suit your every need. MSG provides solutions in a wide range of industry verticals in market sizing, analysis, and intelligent business insights. MSG has experienced research analysts who are proficient at digging deep and providing various customizable data that help you make decisions with clarity, confidence, and impact. Furthermore, Market Statsville Group already benefited more than 1,000 companies each year for their revenue planning. It helped them take their disruptions/innovations early to the market by providing them research ahead of the curve.
MSG has an entire repository of research reports on more than 1,000 niche industries, 3,000 high-growth potentials markets, 5,000 data sets, and more than 12,000 company profiles.
Contact Us:
Market Statsville Group
416, East Standsberry Street, Perkins, Oklahoma 74059, USA
USA: +1-580-205-2707 | +91 702 496 8807
Email: sales@marketstatsville.com
Want to Review Complete Market Research Report